Arbutus Biopharma Corp represents values of innovation, collaboration, and dedication to improving the lives of patients. The company's corporate philosophy is centered around developing and commercializing transformative therapies for the treatment of infectious diseases and advancing the field of RNA interference (RNAi). Arbutus Biopharma Corp employs a rigorous scientific approach combined with strategic partnerships to drive drug discovery and development. With a focus on RNAi therapeutics, the company strives to address unmet medical needs and make a significant impact in the fight against viral diseases. Arbutus Biopharma Corp's commitment to excellence and forward-thinking solutions sets them apart in the biopharmaceutical industry.

Arbutus Biopharma Corp primarily operates in the United States and Canada. This global biopharmaceutical company focuses on developing a range of innovative therapeutic products to treat viral infections. With a strong presence in North America, Arbutus Biopharma Corp aims to address unmet medical needs through its cutting-edge research and development initiatives.

Arbutus Biopharma Corp has achieved several significant milestones in its history. The company successfully developed a proprietary lipid nanoparticle delivery system known as LNP, which has been extensively utilized for the delivery of RNA therapeutics. Additionally, Arbutus developed ARB-1467, an RNAi therapeutic product candidate for the treatment of chronic hepatitis B virus infection. The company also made progress in creating a pipeline of proprietary RNAi therapeutics targeting different diseases. Moreover, Arbutus has entered into collaborations and partnerships to further advance its research and development efforts. Through these achievements, Arbutus Biopharma Corp has demonstrated its dedication to pioneering innovative therapeutic solutions with the potential to make a substantial impact in the field of biopharmaceuticals.

Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is a Vancouver-based biopharmaceutical company focused on discovering, developing, and commercializing innovative antiviral therapies. Established in 2007, Arbutus Biopharma Corp has a rich history of scientific advancements and partnerships in the field of RNA interference (RNAi) technology. This technology aims to silence disease-causing genes, offering potential treatments for viral infections, including hepatitis B and C, as well as various liver and respiratory diseases. Through its commitment to research and development, Arbutus Biopharma Corp strives to transform the lives of patients worldwide by addressing critical unmet medical needs.

The main competitors of Arbutus Biopharma Corp in the market include Gilead Sciences, Inc., Alnylam Pharmaceuticals, Inc., and Vertex Pharmaceuticals Incorporated.

Arbutus Biopharma Corp is primarily active in the biopharmaceutical industry.

The business model of Arbutus Biopharma Corp revolves around researching and developing novel therapies for the treatment of viral diseases. The company focuses on discovering and advancing a pipeline of drug candidates that utilize RNA interference (RNAi) technology. By harnessing the power of RNAi, Arbutus Biopharma aims to silence or inhibit the genes responsible for viral replication, ultimately preventing the spread and progression of viral infections. This innovative approach shows promise in addressing diseases such as hepatitis B and hepatitis D. Arbutus Biopharma Corp aims to leverage its expertise and strategic collaborations to advance these therapies and improve patient outcomes.

Коефициентът на цена спрямо печалбата (КЦП) на Arbutus Biopharma е -8,40.

Коефициентът на цена към оборот (KUV) на Arbutus Biopharma е 93,46.

AlleAktien качественият резултат за Arbutus Biopharma е 5/10.

очаквана Arbutus Biopharma оборотът е 6,73 млн. USD.

очаквана Arbutus Biopharma печалба е -74,92 млн. USD.

Arbutus Biopharma Corp is a bio-pharmaceutical company focused on the development of innovative therapies for the treatment of viral infections. The company operates in three main areas: therapeutics for the treatment of Hepatitis B virus (HBV), Lipid-Mediated Therapeutics™, and RNAi technology. In the HBV therapeutics segment, Arbutus Biopharma is developing a range of drugs aimed at completely eliminating HBV. The company focuses on the discovery and development of Toll-like receptor (TLR) antagonists and other antiviral drugs that harness the immune system to cure diseases. Arbutus Biopharma Corp has partnered with Roivant Sciences to support additional therapeutics in clinical development. In the Lipid-Mediated Therapeutics™ area, the company is developing drugs for the treatment of rare lung diseases and various infectious diseases. The company's platform utilizes non-viral, lipid-mediated delivery of mRNA transferred to cell cultures. Arbutus Biopharma Corp also includes RNAi technology in its product range. This technology utilizes RNA interference to accelerate the development process of RNA-based therapeutics. The company has several RNAi-based therapeutics in clinical development. Arbutus Biopharma Corp has entered into partnerships with various other companies to promote their developments and products. Additionally, the company offers contract development and manufacturing services to the pharmaceutical and biotechnology industries. Arbutus Biopharma Corp is a research and development-focused company. The company aims to develop drugs that meet the needs of the global healthcare sector and improve the lives of patients. The long-term vision of Arbutus Biopharma is to become a leading company in the healthcare industry.

Arbutus Biopharma разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за Arbutus Biopharma в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Arbutus Biopharma е CA03879J1003.

WKN на Arbutus Biopharma е A14XMD.

Тикерът на Arbutus Biopharma е ABUS.

През последните 12 месеца Arbutus Biopharma изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Arbutus Biopharma да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на Arbutus Biopharma в момента е .

Arbutus Biopharma изплаща дивидент на тримесечие. Той се разпределя в месеците .

Arbutus Biopharma платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

Arbutus Biopharma се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Arbutus Biopharma на 1.08.2024 г. в размер на 0 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 1.08.2024 г..

Последното дивидентно плащане беше извършено на 1.08.2024 г..

През година 2023 Arbutus Biopharma изплати 0 USD под формата на дивиденти.

Дивидентите от Arbutus Biopharma се изплащат в USD.